Segall Bryant & Hamill LLC Cuts Stock Position in Denali Therapeutics Inc. $DNLI

Segall Bryant & Hamill LLC decreased its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 4.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 510,543 shares of the company’s stock after selling 26,457 shares during the quarter. Segall Bryant & Hamill LLC owned about 0.32% of Denali Therapeutics worth $9,802,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Capricorn Fund Managers Ltd purchased a new position in Denali Therapeutics in the fourth quarter valued at about $1,027,000. Baillie Gifford & Co. raised its stake in shares of Denali Therapeutics by 6.2% during the fourth quarter. Baillie Gifford & Co. now owns 12,310,889 shares of the company’s stock valued at $203,253,000 after purchasing an additional 719,304 shares during the period. B. Metzler seel. Sohn & Co. AG purchased a new stake in shares of Denali Therapeutics during the fourth quarter valued at approximately $1,841,000. Aberdeen Group plc lifted its position in shares of Denali Therapeutics by 82.6% during the fourth quarter. Aberdeen Group plc now owns 2,032,967 shares of the company’s stock worth $33,564,000 after purchasing an additional 919,381 shares in the last quarter. Finally, Pictet Asset Management Holding SA lifted its position in shares of Denali Therapeutics by 166.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,329,108 shares of the company’s stock worth $21,981,000 after purchasing an additional 829,946 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Wall Street Analysts Forecast Growth

DNLI has been the subject of several analyst reports. Stifel Nicolaus set a $41.00 target price on shares of Denali Therapeutics in a research note on Monday, June 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a report on Friday, July 17th. Sanford C. Bernstein reissued a “hold” rating on shares of Denali Therapeutics in a research report on Monday, June 22nd. Morgan Stanley raised their target price on Denali Therapeutics from $35.00 to $36.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Finally, UBS Group restated a “buy” rating on shares of Denali Therapeutics in a research note on Tuesday, June 16th. Thirteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $35.17.

Denali Therapeutics Stock Performance

Denali Therapeutics stock opened at $23.02 on Monday. The stock has a market cap of $3.65 billion, a P/E ratio of -7.99 and a beta of 1.01. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 0.01. The stock has a 50 day moving average of $23.12 and a 200-day moving average of $21.09. Denali Therapeutics Inc. has a 52 week low of $12.58 and a 52 week high of $27.30.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04. During the same quarter last year, the company posted ($0.78) EPS. On average, analysts expect that Denali Therapeutics Inc. will post -2.73 EPS for the current fiscal year.

Denali Therapeutics Profile

Denali Therapeutics is a clinical?stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine?rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti?TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.